-
市场
-
产品
-
资讯
-
Moo社区
-
课堂
-
查看更多
-
功能介绍
-
费用费用透明,无最低余额限制
投资选择、功能介绍、费用相关信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 浅色
Is Now An Opportune Moment To Examine Intco Medical Technology Co., Ltd. (SZSE:300677)?
Is Now An Opportune Moment To Examine Intco Medical Technology Co., Ltd. (SZSE:300677)?
While Intco Medical Technology Co., Ltd. (SZSE:300677) might not be the most widely known stock at the moment, it saw significant share price movement during recent months on the SZSE, rising to highs of CN¥39.58 and falling to the lows of CN¥22.57. Some share price movements can give investors a better opportunity to enter into the stock, and potentially buy at a lower price. A question to answer is whether Intco Medical Technology's current trading price of CN¥23.50 reflective of the actual value of the mid-cap? Or is it currently undervalued, providing us with the opportunity to buy? Let's take a look at Intco Medical Technology's outlook and value based on the most recent financial data to see if there are any catalysts for a price change.
See our latest analysis for Intco Medical Technology
Is Intco Medical Technology still cheap?
Intco Medical Technology appears to be overvalued by 30% at the moment, based on my discounted cash flow valuation. The stock is currently priced at CN¥23.50 on the market compared to my intrinsic value of CN¥18.09. Not the best news for investors looking to buy! Furthermore, Intco Medical Technology's share price also seems relatively stable compared to the rest of the market, as indicated by its low beta. If you believe the share price should eventually reach its true value, a low beta could suggest it is unlikely to rapidly do so anytime soon, and once it's there, it may be hard to fall back down into an attractive buying range.
What kind of growth will Intco Medical Technology generate?
SZSE:300677 Earnings and Revenue Growth July 13th 2022Future outlook is an important aspect when you're looking at buying a stock, especially if you are an investor looking for growth in your portfolio. Buying a great company with a robust outlook at a cheap price is always a good investment, so let's also take a look at the company's future expectations. In the upcoming year, Intco Medical Technology's earnings are expected to increase by 48%, indicating a highly optimistic future ahead. This should lead to more robust cash flows, feeding into a higher share value.
What this means for you:
Are you a shareholder? It seems like the market has well and truly priced in 300677's positive outlook, with shares trading above its fair value. At this current price, shareholders may be asking a different question – should I sell? If you believe 300677 should trade below its current price, selling high and buying it back up again when its price falls towards its real value can be profitable. But before you make this decision, take a look at whether its fundamentals have changed.
Are you a potential investor? If you've been keeping tabs on 300677 for some time, now may not be the best time to enter into the stock. The price has surpassed its true value, which means there's no upside from mispricing. However, the positive outlook is encouraging for 300677, which means it's worth diving deeper into other factors in order to take advantage of the next price drop.
If you want to dive deeper into Intco Medical Technology, you'd also look into what risks it is currently facing. To help with this, we've discovered 3 warning signs (1 is a bit unpleasant!) that you ought to be aware of before buying any shares in Intco Medical Technology.
If you are no longer interested in Intco Medical Technology, you can use our free platform to see our list of over 50 other stocks with a high growth potential.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
尽管Intco医疗科技股份有限公司(SZSE:300677)可能不是目前最广为人知的股票,但近几个月来,它在深圳证交所的股价大幅波动,涨至39.58元的高点,跌至22.57元的低点。一些股价波动可以让投资者有更好的机会买入股票,并有可能以更低的价格买入。一个需要回答的问题是,Intco Medical Technology目前23.5元的交易价格是否反映了中型股的实际价值?或者,它目前被低估了,为我们提供了买入的机会?让我们根据最新的财务数据来看看Intco Medical Technology的前景和价值,看看是否有任何推动价格变化的催化剂。
查看我们对Intco医疗技术的最新分析
Intco医疗技术公司仍然很便宜吗?
根据我的现金流贴现估值,Intco Medical Technology目前的估值似乎被高估了30%。该股目前在市场上的定价为23.50加元,而我的内在价值为18.09加元。对于想要买入的投资者来说,这不是个好消息!此外,Intco Medical Technology的股价与市场其他股票相比似乎也相对稳定,这从其低贝塔指数中可以看出。如果你认为股价最终应该会达到其真实价值,那么较低的贝塔系数可能意味着它不太可能在短期内迅速做到这一点,一旦达到这一水平,可能很难跌回有吸引力的买入区间。
Intco医疗技术将带来怎样的增长?
深交所:2022年7月13日收益和收入增长300677当你考虑购买一只股票时,未来前景是一个重要的方面,特别是如果你是一个寻求投资组合增长的投资者。以低廉的价格收购一家前景稳健的伟大公司永远是一笔不错的投资,所以让我们也来看看该公司的未来预期。在即将到来的一年里,Intco Medical Technology的收益预计将增长48%,预示着未来的高度乐观。这应该会带来更强劲的现金流,从而带来更高的股价。
这对你意味着什么:
你是股东吗?市场似乎已经很好地、真实地反映了300677的积极前景,股票交易价格高于其公允价值。在目前的价格下,股东们可能会问一个不同的问题--我应该卖出吗?如果你认为300677应该在当前价格以下交易,那么在价格跌至实际价值时逢高抛售并再次买入可能是有利可图的。但在你做出这个决定之前,先看看它的基本面是否发生了变化。
你是潜在的投资者吗?如果你关注300677已经有一段时间了,现在可能不是买入这只股票的最佳时机。价格已经超过了它的真实价值,这意味着错误定价不会带来任何好处。然而,积极的前景对300677来说是令人鼓舞的,这意味着为了利用下一次价格下跌,值得更深入地研究其他因素。
如果你想更深入地研究Intco医疗技术,你还可以看看它目前面临的风险。为了帮助解决这个问题,我们发现3个警示标志(1有点令人不快!)在购买Intco医疗技术公司的任何股票之前,你应该意识到这一点。
如果您对Intco医疗科技不再感兴趣,您可以使用我们的免费平台查看我们的其他50多只具有高增长潜力的股票。
对这篇文章有什么反馈吗?担心内容吗? 保持联系直接与我们联系。或者,也可以给编辑组发电子邮件,地址是implywallst.com。
本文由Simply Wall St.撰写,具有概括性。我们仅使用不偏不倚的方法提供基于历史数据和分析师预测的评论,我们的文章并不打算作为财务建议。它不构成买卖任何股票的建议,也没有考虑你的目标或你的财务状况。我们的目标是为您带来由基本面数据驱动的长期重点分析。请注意,我们的分析可能不会将最新的对价格敏感的公司公告或定性材料考虑在内。Simply Wall St.对上述任何一只股票都没有持仓。
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
风险及免责提示
moomoo是Moomoo Technologies Inc.公司提供的金融信息和交易应用程序。
在美国,moomoo上的投资产品和服务由Moomoo Financial Inc.提供,一家受美国证券交易委员会(SEC)监管的持牌主体。 Moomoo Financial Inc.是金融业监管局(FINRA)和证券投资者保护公司(SIPC)的成员。
在新加坡,moomoo上的投资产品和服务是通过Moomoo Financial Singapore Pte. Ltd.提供,该公司受新加坡金融管理局(MAS)监管(牌照号码︰CMS101000) ,持有资本市场服务牌照 (CMS) ,持有财务顾问豁免(Exempt Financial Adviser)资质。本内容未经新加坡金融管理局的审查。
在澳大利亚,moomoo上的金融产品和服务是通过Futu Securities (Australia) Ltd提供,该公司是受澳大利亚证券和投资委员会(ASIC)监管的澳大利亚金融服务许可机构(AFSL No. 224663)。请阅读并理解我们的《金融服务指南》、《条款与条件》、《隐私政策》和其他披露文件,这些文件可在我们的网站 https://www.moomoo.com/au中获取。
在加拿大,通过moomoo应用提供的仅限订单执行的券商服务由Moomoo Financial Canada Inc.提供,并受加拿大投资监管机构(CIRO)监管。
在马来西亚,moomoo上的投资产品和服务是通过Moomoo Securities Malaysia Sdn. Bhd. 提供,该公司受马来西亚证券监督委员会(SC)监管(牌照号码︰eCMSL/A0397/2024) ,持有资本市场服务牌照 (CMSL) 。本内容未经马来西亚证券监督委员会的审查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd., Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc.,和Moomoo Securities Malaysia Sdn. Bhd.是关联公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用浏览器的分享功能,分享给你的好友吧